Kevin N. Heller, MD

Dr. Kevin Heller is a Venture Partner, Oncology at Harbour BioMed. A physician-scientist and drug developer, he has more than 20 years of experience in oncology research across academia and industry, spanning the full spectrum of oncology drug development-from discovery and pre-IND through clinical development, commercialization, and business development.

 

Dr. Heller trained as a Pediatric Oncology Fellow at Memorial Sloan Kettering Cancer Center and later served as an Instructor in Clinical Investigation at The Rockefeller University, where he conducted research in tumor immunology and translational medicine. He then spent six years at Bristol-Myers Squibb, holding roles in early clinical development and the development of the immunotherapy drug ipilimumab.  As the US Medical Lead for ipilimumab, he led the authoring of the FDA-approved label and the Risk Evaluation and Mitigation Strategy (REMS) guidelines for the drug.  He subsequently served as Senior Medical Director at AstraZeneca and as Vice President, Head of Antibody Clinical Development in Immuno-Oncology at Incyte.

 

Dr. Heller has held senior leadership positions at multiple biopharmaceutical companies, including NextCure, Tallac Therapeutics, and Jasper Therapeutics. He currently serves as a consulting Chief Medical Officer for early-stage biotech companies and an advisor to the investment team at Ausangate Capital.

 

Dr. Heller received his M.D. from The George Washington University School of Medicine and his bachelor of science degree in Molecular Biophysics and Biochemistry from Yale University.